Plasmar Trial: Early Alzheimer’s Biomarker Results Increase Diagnostic Certainty
Early disclosure of Alzheimer’s disease blood test results significantly raises physician diagnostic certainty and changes clinical management without increasing patient anxiety or depression, according to findings published in JAMA Neurology on October 5. Medscape reported that the first randomized trial assessing the clinical impact of plasma phosphorylated tau at threonine 217 (p-tau217) and neurofilament light … Read more